Do males and females respond differently to the synthetic cannabinoid MMB-Fubinaca? | Research

The takeaway

An animal study found that the synthetic cannabinoid MMB-Fubinaca produced significantly stronger behavioral and electrophysiological effects in male mice than female mice, all mediated through CB1 receptors.

Readers interested in synthetic cannabinoid pharmacology, sex differences in drug response, or the neuroscience of cannabinoid receptors.

Males showed significantly stronger effects

What the researchers found

MMB-Fubinaca activated CB1 receptors with much greater potency than the standard cannabinoid agonist WIN55,512-2 in both mouse and human brain tissue. In vivo, male mice showed significantly greater behavioral and electrophysiological responses than females, all dependent on CB1 receptor activity.

Why it matters

Synthetic cannabinoids are a major public health concern and are far more potent than plant-derived THC. These sex-based differences in response could mean that risk assessments and emergency treatments may need to account for biological sex.

The numbers in context

MMB-Fubinaca showed much greater potency than WIN55,512-2 at CB1 receptors; male mice showed significantly greater behavioral and electrophysiological effects than females; effects were CB1 receptor-dependent

How the study worked

Combined behavioral, molecular, pharmacological, and electrophysiological approaches in mice, plus in vitro assays using mouse and human brain preparations. CB1 receptor-dependent effects confirmed using antagonists.

What this study cannot tell us

Animal study; findings may not directly translate to humans. Only one synthetic cannabinoid tested. Mechanisms underlying the sex difference were not fully elucidated.

How to read the evidence

Well-designed animal study with multiple methodological approaches, but preclinical only.

When this study was published

Published in 2021; synthetic cannabinoid research continues to evolve rapidly.

The bigger picture

Sex differences in cannabinoid pharmacology are increasingly well documented but rarely factored into public health messaging or clinical management of synthetic cannabinoid poisoning. This study adds to evidence that one-size-fits-all approaches may be inadequate.

Questions still open

Do similar sex differences exist for other synthetic cannabinoids? Are the sex-dependent effects driven by hormonal factors, receptor density differences, or metabolism? Do these animal findings predict sex differences in human emergency presentations?

Common questions

What is MMB-Fubinaca?

MMB-Fubinaca (also called AMB-Fubinaca or FUB-AMB) is a synthetic cannabinoid that acts on CB1 receptors with much greater potency than THC or standard research cannabinoids.

Why did males respond more strongly?

The study confirmed the effects were CB1 receptor-dependent but did not fully explain why males were more sensitive. Sex differences in cannabinoid receptor density, hormonal modulation, or drug metabolism could contribute.

Read the original research

Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca.

Addiction biology, 26(3), e12940

View on PubMed ↗Publisher’s paper ↗

Citation

Oliveira da Cruz, José F; Ioannidou, Christina; Pagano Zottola, Antonio C; Muguruza, Carolina; Gomez-Sotres, Paula; Fernandez, Monica; Callado, Luis F; Marsicano, Giovanni; Busquets-Garcia, Arnau. (2021). Sex-dependent pharmacological profiles of the synthetic cannabinoid MMB-Fubinaca.. Addiction biology, 26(3), e12940. https://doi.org/10.1111/adb.12940